Medigus Ltd. (NASDAQ:MDGS) (“Medigus”), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that it plans to effect 1:15 ratio change of the Company’s American Depositary Receipt, or ADR, program. As a result, the number of ordinary shares of the Company represented by each American Depositary Share, or ADS, will be changed from one (1) ordinary share to fifteen (15) ordinary shares. The effective date anticipated for the ratio change is November 14, 2022 and the Company’s ADSs will continue to be traded on the Nasdaq Capital Market under the symbol “MDGS” with a new CUSIP Number 58471G 409.
Lifecore Biomedical Enters Into $150M In New Financing, Repays its Outstanding Term Loans And Signs New Supply Agreement To Expand HA Fermentation Capacity With Existing Long-Term Customer, Alcon
Lifecore Biomedical, Inc. (NASDAQ:LFCR), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has entered into a broad set of agreements with its long-term customer,
